BUTYRIC ACID AND INULIN IN THE COMBINATION TREATMENT OF ABDOMINAL PAIN IN IRRITABLE BOWEL SYNDROME

Download full text PDF
Issue: 
10
Year: 
2015

A. Nizhevich (1), MD; E. Koroleva (2); E. Astrelina (2); V. Alyangin (1,2), MD 1 -Bashkir State Medical University, Ufa 2 -OOO «Endomed», Gastrocenter Clinic, Ufa

The combination of trimebutine and Zacofalc has been shown to surpass that of trimebutine and lactobacteria in efficacy when comparing the magnitude of pain syndrome (p=0.04) and the intensity of painful sensations (p=0.042). The former combination is an effective agent for the therapeutic correction of abdominal pain in patients with irritable bowel syndrome.
Keywords: 
irritable bowel syndrome
butyric acid
inulin

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Pimanov S.I., Silivonchik N.N. Rimskij III konsensus: Izbrannye raz- dely i kommentarii / Vitebsk: Izdatel'stvo VGMU, 2006; 160 s.
  2. Sheptulin A.A. Rimskie kriterii III sindroma razdrazhennogo kishechni ka: chto my ozhidali i chto my uvideli? // RZhGGK. – 2007; 2: 63–8.
  3. Rey E., Talley N. Irritable bowel syndrome: Novelviews on the epidemiology and potential risk factors // Dig. Liver Dis. – 2009; 41: 772–80.
  4. Gweek A., Wee S., Wong M. et al. The prevalence, symptom characteristics and impact of irritable bowel syndrome in an Asian urban community // Am. J.. Gastroenterol. – 2004; 99: 924–31.
  5. Mangel A., Northcutt A. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients // Aliment. Pharmacol. Ther. – 1999; 13 (Suppl. 2): 77–82.
  6. Ghoshal U., Abraham P., Bhatt C. et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology task force // Indian J. Gastroenterol. – 2008; 27 (1): 22–8.
  7. Whitehead W., Crowell M., Davidoff A. et al. Pain from rectal distension in women with irritable bowel syndrome // Dig. Dis. Sci. – 1997; 42: 796–804
  8. Whitehead W., Holtkotter B., Enck P. et al. Tolerance for rectosigmoid distension in irritable bowel syndrome // Gastroenterology. – 1990; 98: 1187–92
  9. Ardatskaja M.D. Masljanaja kislota i inulin v klinicheskoj praktike: teoreticheskie aspekty i vozmozhnosti klinicheskogo primenenija / M.: Forteprint, 2014; 64 c.
  10. Banasiewicz T., Kaczmarek E., Maik J. et al. Quality of life andthe clinical symptoms at the patients with irritable bowel syndrometreated complementary with protected sodium butyrate // Gastroenterol. Prakt. – 2011; 5: 45–53.
  11. Banasiewicz T., Kaczmarek E., Maik J. et al. The influence of protected sodium butyrate on frequency and severity some clinicalsymptoms at the patients with irritable bowel syndrome // Gastroenterol. Prakt. – 2012; 1: 16–23.
  12. Tarnowski W., Borycka-Kiciak K., Kiciak A. et al. Outcome oftreatment with butyric acid in irritable bowel syndrome – preliminaryreport // Gastroenterol. Prakt. – 2011; 1: 43–8.
  13. Vanhoutvin S., Troost F., Kilkens T. et al. The effects of butyrate enemas on visceral perception in healthy volunteers // Neurogastroenterol. Motil. – 2009; 21 (9): 952–76.
  14. Maev I.V., Kucherjavyj Ju.A., Cheremushkin S.V. Evoljutsija predstavlenij o sindrome razrazhennogo kishechnika. Metodicheskie rekomendatsii dlja vra-chej / M., 2013; 80 s.
  15. Vasil'ev Ju.V. Sindrom razdrazhennogo kishechnika: sovremennye aspekty diagnostiki i terapii // Med. Sovet. – 2014; 4: 72–7.
  16. Nijevitch A., Akhmadeeva E., Sataev V. et al. Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood // J. Nepal. Paediatr. Soc. – 2013; 33 (2): 158–62.
  17. Delvaux M., Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results // J. Int. Med. Res. – 1997; 25 (5): 225–46
  18. Lee H., Kim B. Trimebutine as a modulator of gastrointestinal motility // Arch. Pharm. Res. – 2011; 34 (6): 861–4.
  19. Fioramonti J., Bueno L. Centrally acting agents and visceral sensitivity // Gut. – 2002; 51 (Suppl. 1): 91–5.
  20. Sarnelli G. Gut microbiota and irritable bowel syndrome: a further link between the big brain – little brain axis // J. Prob. Health. – 2014; 2 (2): 107.
  21. Lee K., Tack J. Altered intestinal microbiota in irritable bowel syndrome // Neurogastroenterol. Motil. – 2010; 22 (5): 493–8.
  22. Collins S., Denou E., Verdu E. et al. The putativerole of the intestinal microbiota in the irritable bowel syndrome // Dig. Liver Dis. – 2009; 41 (12): 850–3
  23. Sudo N., Chida Y., Aiba Y. et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice // J. Physiol. – 2004; 558 (Pt. 1): 263–75.
  24. Kunze W., Mao Y., Wang B. et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening // J. Cell. Mol. Med. – 2009; 13 (8B): 2261–70.
  25. Salonen A., de Vos W., Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives // Microbiology. – 2010; 156 (Pt. 11): 3205–15.
  26. Topping D., Clifton P. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides // Physiol. Rev. – 2001; 81 (3): 1031–64.
  27. Zaski A., Banaszkiewicz A., Walkowiak J. Butyric acid in irritable bowel syndrome // Prz. Gastroenterol. – 2013; 8 (6): 350–3.
  28. Guilloteau P., Martin L., Eeckhaut V. et al. From the gut to the peripheral tissues: the multiple effects of butyrate // Nutr. Res. Rev. – 2010; 23 (2): 366–84
  29. Erofeev N.P., Radchenko V.G., Seliverstov P.V. Klinicheskaja fiziolo gija tolstoj kishki. Mehanizmy dejstvija korotkotsepochechnyh zhirnyh kislot v norme i pri patologii: monografija / SPb: Forte Print, 2012; 56 s.